Effect of increasing doses of long chain $n-3$ PUFA on vascular function: MARINA – a randomised controlled trial

T. A. B. Sanders$^1$, Z. Maniou$^1$, W. L. Hall$^1$, F. Lewis$^1$, P. T. Seed$^2$ and P. J. Chowienczyk$^3$

$^1$School of Medicine, King’s College London, Diabetes and Nutritional Sciences Division, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK, $^2$Division of Women’s Health, St Thomas’ Hospital, London SE1 7EH, UK and $^3$Cardiovascular Division, St Thomas’ Hospital, London SE1 7EH, UK

Dietary EPA and DHA intakes have been positively associated with improved endothelial function in young adults$^{(1)}$. However, Egert et al.$^{(2)}$ reviewed thirty-three intervention trials investigating the effects of $n-3$ PUFA on fasting and/or postprandial endothelial function and no clear conclusion could be drawn because of the small numbers in many trials and inconsistent methodology. The MARINA study (ISRCTN66664610) was a randomised controlled trial designed to test the hypothesis that increasing doses of EPA and DHA (0.45 g, 0.9 g and 1.8 g/d; equivalent to consuming 1, 2 or 4 portions of oily fish per week) taken for 1 year have favourable effects on endothelial function measured by flow-mediated dilatation (FMD) of the brachial artery. EPA + DHA and placebo ( olive oil BP) were administered as supplements and the study was conducted double blind. A total of 367 non-smoking participants (142 men, 225 women aged 45–70 years, mean age 55 years) were randomised to treatment and a total of 312 subjects completed; data was available for analysis on 311 subjects for baseline and follow-up measurements of endothelial function. The mean (95% CI) increase in erythrocyte EPA compared with placebo was 0.74 (0.56–0.91), 1.31 (1.13–1.48) and 2.51 (2.33–2.69) wt % on 0.45 g/d, 0.9 g/d and 1.8 g/d, respectively ($P<0.0001$). Significant reductions in plasma TAG concentrations ($P=0.002$) were observed in women but not men: in comparison with placebo changes were $-0.06$ ($-0.21$ to $0.09$), $-0.12$ ($-0.27$ to $0.03$) and $-0.29$ ($-0.44$ to $-0.14$) mmol/l on doses of 0.45, 0.9 and 1.8 g/d, respectively. No significant treatment effects were noted for ambulatory blood pressure or arterial stiffness (pulse wave velocity). FMD was lower in men than in women ($P<0.0001$) and decreased with age ($P=0.781$).

Our results are consistent with a cross-sectional survey in 3045 adults$^{(3)}$ that found no significant relationship between the $n-3$ LCP intake with FMD but a trend for FMD to be 0.1 and 0.27% lower on the highest compared with lowest intake in men and women, respectively. Our results indicate that intakes of $n-3$ LCP up to 1.8 g/d do not influence endothelial function in healthy non-smoking adults at moderate risk of CVD.

Funding for this work was provided by the Food Standards Agency and the Department of Health, England (Project code N02041).